Abstract
Immunotherapy already became an integral part of complex therapy in oncology. Immunotherapy can be both non antigen specific or antigen specific, targeting tumour antigens by various approaches.
Progress in the basic research leads to better understanding of mechanisms of interaction between immune system and tumours. This allows us to target the structures or mechanisms involved in the process of carcinogenesis.
In this review, we report a list of therapeutic agents which are already approved or are tested in clinical trials.